Patients with diabetes mellitus are at an increased risk of cardiovascular disease. Cardiovascular outcome trials have shown GLP-1RAs decrease the primary composite outcome of the first occurrence of major adverse cardiovascular events (MACE) in patients with diabetes. Additionally, select GLP-1RAs have also shown improved cardiovascular outcomes in patients without diabetes who are either overweight (BMI ≥ 27), or obese (BMI ≥ 30). There have also been encouraging results in patients with heart failure with preserved ejection fraction. There is increasing evidence showing GLP-1RAs are beneficial across the cardiometabolic spectrum of disease. Implementation of these therapeutics into clinical practice is important to improve cardiovascular risk.
Keyphrases
- cardiovascular disease
- cardiovascular events
- type diabetes
- end stage renal disease
- clinical practice
- body mass index
- wild type
- weight gain
- weight loss
- coronary artery disease
- chronic kidney disease
- newly diagnosed
- ejection fraction
- healthcare
- primary care
- cardiovascular risk factors
- small molecule
- emergency department